Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine patch open-label extension in Alzheimer's
NCT00219232Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2003
- Primary completion
- Jul 2006
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
A Phase 3 trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Started Feb 2003; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00219232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00219232.